Metin Ayğar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Metin Ayğar has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Erbil Karaman
Faculty of Medicine, Department of Gynecology and Obstetrics, Van Yuzuncu Yil University, Van, Turkey
2 shared publications - Mustafa Güven
Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey
2 shared publications - Onur Karaaslan
Faculty of Medicine, Department of Gynecology and Obstetrics, Van Yuzuncu Yil University, Van, Turkey
2 shared publications - Serhat Uygur
Faculty of Medicine, Van Yuzuncu Yil University, Van, Turkey
2 shared publications Özgür Arslan
Department of Gynecology and Obstetrics, Muş State Hospital, Muş, Turkey
2 shared publications- Esra Buse Ergün
UNIVERSITY OF HEALTH SCIENCES, İSTANBUL KARTAL DR. LÜTFİ KIRDAR HEALTH RESEARCH CENTER, DEPARTMENT OF SURGICAL MEDICAL SCIENCES, DEPARTMENT OF OBSTETRICS AND GYNAECOLOGY
1 shared publication
Latest Publications
- 11 July 2026
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 23 (2) , 154-159
Comparison of Liver Function-Based Scoring Systems and Development of a Novel Predictive Model for Intrahepatic Cholestasis of Pregnancy: A Retrospective Cohort Study
Objective: Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent pregnancy-specific liver disorder, associated with significant risks of adverse perinatal outcomes, including preterm birth and stillbirth. The diagnostic gold standard, serum bile acid measurement, has limited availability, necessitating alternative diagnostic tools based on routine laboratory parameters. This study aimed to evaluate the diagnostic utility of the Albumin-Bilirubin (ALBI) score, Aspartate Aminotransferase-to-Platelet Ratio Index (APRI), Platelet-Albumin-Bilirubin (PALBI) index, and Fibrinogen-to-Albumin Ratio (FAR) in patients with ICP. A further objective was to develop a novel predictive model by integrating these scores with hematological markers and to assess the association between these models and perinatal outcomes.Methods: This retrospective cohort study included 65 pregnant women diagnosed with ICP and 67 healthy pregnant women as controls. Data were collected between January 2020 and December 2024 at a tertiary maternity center. The ALBI, APRI, PALBI, and FAR scores, alongside inflammatory markers such as the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Red Cell Distribution Width (RDW), were calculated from routine biochemical and hematological analyses. The diagnostic performance of each score was assessed using Receiver Operating Characteristic (ROC) curve analysis. A novel composite score was subsequently developed using multivariate logistic regression.Results: The ALBI, APRI, PALBI, and FAR scores were all significantly elevated in the ICP cohort compared to the control group (p < 0.001 for all). Among the individual models, the APRI score demonstrated the highest diagnostic performance (Area Under the Curve [AUC] = 0.83). A newly developed composite score, integrating ALBI, NLR, PLR, and RDW, yielded superior diagnostic accuracy (AUC = 0.86), with a sensitivity of 81% and a specificity of 75%. This novel score also showed a significant correlation with adverse perinatal outcomes, including lower gestational age at birth, reduced birth weight, and higher rates of admission to the neonatal intensive care unit (NICU).Conclusion: Scoring systems derived from routine biochemical and hematological parameters are valuable adjunctive tools for the diagnosis of ICP. The novel composite score proposed herein offers a practical, cost-effective, and highly accurate method for early diagnosis and risk stratification, particularly in clinical settings where bile acid assays are not readily accessible.
- 11 July 2026
- Published by Ministry of Health, Ankara City Hospital in Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi
- Vol. 23 (2) , 154-159
Comparison of Liver Function-Based Scoring Systems and Development of a Novel Predictive Model for Intrahepatic Cholestasis of Pregnancy: A Retrospective Cohort Study
Objective: Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent pregnancy-specific liver disorder, associated with significant risks of adverse perinatal outcomes, including preterm birth and stillbirth. The diagnostic gold standard, serum bile acid measurement, has limited availability, necessitating alternative diagnostic tools based on routine laboratory parameters. This study aimed to evaluate the diagnostic utility of the Albumin-Bilirubin (ALBI) score, Aspartate Aminotransferase-to-Platelet Ratio Index (APRI), Platelet-Albumin-Bilirubin (PALBI) index, and Fibrinogen-to-Albumin Ratio (FAR) in patients with ICP. A further objective was to develop a novel predictive model by integrating these scores with hematological markers and to assess the association between these models and perinatal outcomes.Methods: This retrospective cohort study included 65 pregnant women diagnosed with ICP and 67 healthy pregnant women as controls. Data were collected between January 2020 and December 2024 at a tertiary maternity center. The ALBI, APRI, PALBI, and FAR scores, alongside inflammatory markers such as the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Red Cell Distribution Width (RDW), were calculated from routine biochemical and hematological analyses. The diagnostic performance of each score was assessed using Receiver Operating Characteristic (ROC) curve analysis. A novel composite score was subsequently developed using multivariate logistic regression.Results: The ALBI, APRI, PALBI, and FAR scores were all significantly elevated in the ICP cohort compared to the control group (p < 0.001 for all). Among the individual models, the APRI score demonstrated the highest diagnostic performance (Area Under the Curve [AUC] = 0.83). A newly developed composite score, integrating ALBI, NLR, PLR, and RDW, yielded superior diagnostic accuracy (AUC = 0.86), with a sensitivity of 81% and a specificity of 75%. This novel score also showed a significant correlation with adverse perinatal outcomes, including lower gestational age at birth, reduced birth weight, and higher rates of admission to the neonatal intensive care unit (NICU).Conclusion: Scoring systems derived from routine biochemical and hematological parameters are valuable adjunctive tools for the diagnosis of ICP. The novel composite score proposed herein offers a practical, cost-effective, and highly accurate method for early diagnosis and risk stratification, particularly in clinical settings where bile acid assays are not readily accessible.
- Open Access
- 22 August 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (5) , 1847
Correction: Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study
- 22 August 2025
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 312 (5) , 1847
Open AccessCorrection: Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study
- 22 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (2) , 223-227
Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study
Purpose Ectopic pregnancy (EP) constitutes 1–2% of all pregnancies. Methotrexate (MTX) is commonly used in treating EP, but it has some limitations and potential side effects. Clinical studies have shown that letrozole, an aromatase inhibitor, may potentially be used in conjunction with MTX therapy. In our study, we explored the efficacy of adding letrozole to MTX in managing EP. Methods Between June 2021 and September 2022, a total of 60 patients diagnosed with EP at the Faculty of Medicine, Yüzüncü Yıl University, were randomly divided into two groups. Group 1 received MTX alone, while Group 2 received a combination of MTX and letrozole. The primary outcome measure was the change in serum β-hCG levels. Secondary outcomes included the need for surgical intervention and the occurrence of side effects. Results Both groups demonstrated similar success rates in treatment, and there was no significant difference between the MTX and MTX + letrozole groups regarding the need for surgical intervention. Although β-hCG levels declined more rapidly in the MTX + letrozole group, these decreases were not statistically significant. The combination of MTX and letrozole in the treatment of ectopic pregnancy has shown similar efficacy to single-dose MTX. Conclusion Letrozole may offer a potential contribution to MTX therapy by providing a more pronounced reduction in β-hCG levels, but further research with larger sample sizes and longer follow-up periods is needed to confirm these findings.
- 22 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 311 (2) , 223-227
Evaluating single-dose methotrexate alone versus methotrexate with letrozole for treating ectopic pregnancy: a comparative study
Purpose Ectopic pregnancy (EP) constitutes 1–2% of all pregnancies. Methotrexate (MTX) is commonly used in treating EP, but it has some limitations and potential side effects. Clinical studies have shown that letrozole, an aromatase inhibitor, may potentially be used in conjunction with MTX therapy. In our study, we explored the efficacy of adding letrozole to MTX in managing EP. Methods Between June 2021 and September 2022, a total of 60 patients diagnosed with EP at the Faculty of Medicine, Yüzüncü Yıl University, were randomly divided into two groups. Group 1 received MTX alone, while Group 2 received a combination of MTX and letrozole. The primary outcome measure was the change in serum β-hCG levels. Secondary outcomes included the need for surgical intervention and the occurrence of side effects. Results Both groups demonstrated similar success rates in treatment, and there was no significant difference between the MTX and MTX + letrozole groups regarding the need for surgical intervention. Although β-hCG levels declined more rapidly in the MTX + letrozole group, these decreases were not statistically significant. The combination of MTX and letrozole in the treatment of ectopic pregnancy has shown similar efficacy to single-dose MTX. Conclusion Letrozole may offer a potential contribution to MTX therapy by providing a more pronounced reduction in β-hCG levels, but further research with larger sample sizes and longer follow-up periods is needed to confirm these findings.